Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study

Background: Glecaprevir/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pei-Yuan Su, Yang-Yuan Chen, Jun-Hung Lai, Hung-Ming Chen, Chih-Ta Yao, I-Ling Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Shun-Sheng Wu, Fu-Yuan Siao, Hsu-Heng Yen
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	hepatitis C therapy cirrhosis compensated cirrhosis Medicine R
Acceso en línea:	https://doaj.org/article/f321209ac5414ae2ad7e871bb6cb7149
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f321209ac5414ae2ad7e871bb6cb7149
record_format	dspace
spelling	oai:doaj.org-article:f321209ac5414ae2ad7e871bb6cb71492021-11-25T18:00:45ZReal-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study10.3390/jcm102252362077-0383https://doaj.org/article/f321209ac5414ae2ad7e871bb6cb71492021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5236https://doaj.org/toc/2077-0383Background: Glecaprevir/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis in a real-world setting. Methods: We evaluated the real-world safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis from five hospitals in the Changhua Christian Care System, who underwent treatment between August 2018 and October 2020. The primary endpoint was a sustained virological response observed 12 weeks after completion of the treatment. Results: Ninety patients, including 70 patients who received the 12-week therapy and 20 patients who received the 8-week therapy, were enrolled. The mean age of the patients was 65 years, and 57.8% of the patients were males. Sixteen (17.8%) patients had end-stage renal disease, and 15 (16.7%) had co-existing hepatoma. The hepatitis C virus genotypes 1 (40%) and 2 (35.6%) were most common. The common side effects included anorexia (12.2%), pruritus (7.8%), abdominal discomfort (7.8%), and malaise (7.8%). Laboratory adverse grade ≥3 events included anemia (6.3%), thrombocytopenia (5.1%), and jaundice (2.2%). The overall sustained virological response rates were 94.4% and 97.7% in the intention-to-treat and per-protocol analyses, respectively. Conclusions: the glecaprevir/pibrentasvir treatment regimen was highly effective and well tolerated among patients with compensated cirrhosis in the real-world setting.Pei-Yuan SuYang-Yuan ChenJun-Hung LaiHung-Ming ChenChih-Ta YaoI-Ling LiuYa-Huei ZengSiou-Ping HuangYu-Chun HsuShun-Sheng WuFu-Yuan SiaoHsu-Heng YenMDPI AGarticlehepatitis Ctherapycirrhosiscompensated cirrhosisMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5236, p 5236 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatitis C therapy cirrhosis compensated cirrhosis Medicine R
spellingShingle	hepatitis C therapy cirrhosis compensated cirrhosis Medicine R Pei-Yuan Su Yang-Yuan Chen Jun-Hung Lai Hung-Ming Chen Chih-Ta Yao I-Ling Liu Ya-Huei Zeng Siou-Ping Huang Yu-Chun Hsu Shun-Sheng Wu Fu-Yuan Siao Hsu-Heng Yen Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
description	Background: Glecaprevir/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis in a real-world setting. Methods: We evaluated the real-world safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis from five hospitals in the Changhua Christian Care System, who underwent treatment between August 2018 and October 2020. The primary endpoint was a sustained virological response observed 12 weeks after completion of the treatment. Results: Ninety patients, including 70 patients who received the 12-week therapy and 20 patients who received the 8-week therapy, were enrolled. The mean age of the patients was 65 years, and 57.8% of the patients were males. Sixteen (17.8%) patients had end-stage renal disease, and 15 (16.7%) had co-existing hepatoma. The hepatitis C virus genotypes 1 (40%) and 2 (35.6%) were most common. The common side effects included anorexia (12.2%), pruritus (7.8%), abdominal discomfort (7.8%), and malaise (7.8%). Laboratory adverse grade ≥3 events included anemia (6.3%), thrombocytopenia (5.1%), and jaundice (2.2%). The overall sustained virological response rates were 94.4% and 97.7% in the intention-to-treat and per-protocol analyses, respectively. Conclusions: the glecaprevir/pibrentasvir treatment regimen was highly effective and well tolerated among patients with compensated cirrhosis in the real-world setting.
format	article
author	Pei-Yuan Su Yang-Yuan Chen Jun-Hung Lai Hung-Ming Chen Chih-Ta Yao I-Ling Liu Ya-Huei Zeng Siou-Ping Huang Yu-Chun Hsu Shun-Sheng Wu Fu-Yuan Siao Hsu-Heng Yen
author_facet	Pei-Yuan Su Yang-Yuan Chen Jun-Hung Lai Hung-Ming Chen Chih-Ta Yao I-Ling Liu Ya-Huei Zeng Siou-Ping Huang Yu-Chun Hsu Shun-Sheng Wu Fu-Yuan Siao Hsu-Heng Yen
author_sort	Pei-Yuan Su
title	Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
title_short	Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
title_full	Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
title_fullStr	Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
title_full_unstemmed	Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
title_sort	real-world experience of chronic hepatitis c-related compensated liver cirrhosis treated with glecaprevir/pibrentasvir: a multicenter retrospective study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f321209ac5414ae2ad7e871bb6cb7149
work_keys_str_mv	AT peiyuansu realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT yangyuanchen realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT junhunglai realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT hungmingchen realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT chihtayao realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT ilingliu realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT yahueizeng realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT sioupinghuang realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT yuchunhsu realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT shunshengwu realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT fuyuansiao realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy AT hsuhengyen realworldexperienceofchronichepatitiscrelatedcompensatedlivercirrhosistreatedwithglecaprevirpibrentasviramulticenterretrospectivestudy
_version_	1718411778215378944

Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study

Ejemplares similares